Gilda Mark, APRN
Psychiatric/Mental Health · Fort Collins, CONPI 1700124617
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 218 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 33.2% of the total. 2025 is the largest year on record at $2,673, more than ten times the $250 reported in 2021. Among psychiatric/mental health clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $35.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$976
- Otsuka America Pharmaceutical, Inc.$719
- E.r. Squibb & Sons, L.L.C.$296
- plus $215 from 6 others
What the payments were for
- Food & beverage$7,57098%
- Education$1782%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 58 | $2,569 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 49 | $1,693 |
| Alkermes, Inc. | 41 | $1,279 |
| Teva Pharmaceuticals USA, Inc. | 26 | $976 |
| Otsuka America Pharmaceutical, Inc. | 27 | $719 |
| E.r. Squibb & Sons, L.L.C. | 8 | $296 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $82 |
| Lundbeck LLC | 2 | $38 |
| Johnson & Johnson | 1 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| AbbVie | 1 | $25 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$1,213
- LYBALVI$1,028
- CAPLYTA$706
- ARISTADA$424
- ABILIFY MAINTENA$218
- COBENFY$131
- ABILIFY ASIMTUFII$106
- REXULTI$101
How this compares
$7,748 in reported general payments places this provider in the 95th percentile of 873 psychiatric/mental health providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 28 | $236,571 |
| Austedo XrDeutetrabenazine | 12 | $60,332 |
| LybalviOlanzapine/Samidorphan Malate | 27 | $44,589 |
| VraylarCariprazine Hcl | 19 | $25,822 |
| RexultiBrexpiprazole | 14 | $21,592 |
| Clozapine | 71 | $5,025 |
| DepakoteDivalproex Sodium | 19 | $4,872 |
| Divalproex Sodium ErDivalproex Sodium | 58 | $3,879 |
| Lurasidone Hcl | 15 | $3,114 |
| Olanzapine | 127 | $2,834 |
| Fluvoxamine Maleate | 31 | $2,447 |
| Aripiprazole | 81 | $2,318 |
| Lamotrigine | 123 | $2,071 |
| Buspirone Hcl | 88 | $1,716 |
| Risperidone | 107 | $1,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $2,569 | $236,57128 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $976 | $60,33212 claims |
| Alkermes, Inc.Lybalvi | $1,279 | $44,58927 claims |
| AbbVieVraylar | $25 | $25,82219 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $719 | $21,59214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 873 psychiatric/mental health providers in Colorado.
Other psychiatric/mental health in Fort Collins
- Nancy HillFort Collins$6K
- Lanny DouglasFort Collins$6K
- Chelsie MonroeLittleton$998K
- Audrey StrockDenver$499K
- Pinkie FittsAurora$444K
- Mark JankelowColorado Springs$287K
- Cristi BundukamaraColorado Springs$230K
- Deborah YorkDenver$158K
- Shelley AbadiLakewood$19K
- James AndersonWheat Ridge$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.